



New Lower Taxotere® Prices for Oncology Associates Members!

Oncology Associates is pleased to announce a new agreement with **Aventis**, effective February 15, 2004. This agreement will enable OA Members to receive the maximum discounting structure available for **Taxotere®**.

OA Members currently attached to the OA Taxotere® agreement with a signed declaration letter on file were automatically enrolled in the new contract **February 15, 2004**.

Contract Terms: February 15, 2004 to June 30, 2004

Your current contract price is based on all Taxotere® purchases between January 1, 2003 to June 30, 2003. The transition period (2-15-04 to 6-30-04) of the new contract sets standardized discounts, regardless of prior market share performance.

1. OA Members who purchased less than \$500,000 of Taxotere® will receive a contract price of 10% below WAC.
2. OA Members who purchased more than or equal to \$500,000 of Taxotere® will receive a contract price of 13% below WAC.

Product	NDC
Taxotere® 20 mg Sol	00075-8001-20
Taxotere® 80 mg Sol	00075-8001-80

Contract Terms: July 1, 2004 to December 31, 2005

- > Discounts below WAC will be based on your Taxotere® purchases as a percentage of your practice's total combined purchases of Taxotere®, Paclitaxel, and Gemcitabine measured in equivalent dosing units.
- > Individual practice performance will be measured each calendar quarter according to the schedule listed below.
- > **Data must be reported by practices on a quarterly basis on the Aventis web site by deadlines specified below.** More details to follow from OA on this topic.

Measurement Period	Reporting Deadline	Practice Specific Contract Price Start Date
01/01/04 - 03/31/04	05/15/04	07/01/04 - 09/30/04
04/01/04 - 06/30/04	08/15/04	10/01/04 - 12/31/04
07/01/04 - 09/30/04	11/15/04	01/01/05 - 03/31/05

For more details about this exciting agreement, contact Oncology Associates at 888-732-7352.



Wyeth/Genetics Institute Contract Renewal for Neumega®

Oncology Associates is pleased to renew the following agreement for Neumega®, effective January 1, 2004. The contract provides discounted pricing for the product Neumega® in 5 mg vial and 5 mg vial 7/bx quantities.

Neumega® is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are high risk of severe thrombocytopenia.

Please contact Oncology Associates at 888-732-7352 for more information about the agreement for Neumega®.

NDC#	Vial Size	Vials per Box
58394-004-01	5 mg	1 vial; 1x10
58394-004-02	5 mg	1x7



Ethylol Protect Program®

Call (800) 877-2467
9:00 am - 6:00 pm

In this changing reimbursement environment, it's critical to have access to the most current information relating to reimbursement of Ethylol®. The Ethylol Protect Program reimbursement counselors provide information and assistance regarding:

- > Product and procedure coding recommendations
- > Patient-specific benefit verifications
- > Assistance determining prior authorization requirements
- > Claim review assistance
- > Claim denial appeal assistance